ALFA Finder| Value | ₹208.0 Cr |
|---|---|
| Execution period | Guarantee valid till March 31, 2030; facility valid for 3 years |
NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,334.10
- Market cap
- ₹55,016 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.5×Sector 43.7×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Annual General Meeting
Gland Pharma's shareholders approved the appointment of Xingli Wang as Non-Executive Non-Independent Director via postal ballot. The ordinary resolution passed with 97.07% of votes in favour.
Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Other debt & borrowing announcements
All →Sarveshwar Foods Debt & Borrowing: ₹25 Cr
Sarveshwar Foods signed an unsecured loan agreement lending up to Rs.25 crore to its 99%-owned subsidiary, Sarveshwar Overseas. The loan is at arm's length.
- Value
- ₹25.00 Cr
Godrej Agrovet Debt & Borrowing: ₹425 Cr
Godrej Agrovet Limited announced record dates for the maturity payment of eight Commercial Paper (CP) series. Total repayment for these obligations amounts to ₹425 Crore.
- Value
- ₹425.0 Cr
Ugro Capital Debt & Borrowing: ₹3.62 Cr
Ugro Capital paid interest on three NCD series totalling Rs 3.62 Crore on 13 November 2026. Payments were made ahead of the 15-16 November due dates.
- Value
- ₹3.62 Cr
Moneyboxx Finance Debt & Borrowing: ₹0.07 Cr
Moneyboxx Finance paid Rs 0.07 Crore interest on its listed senior secured NCDs on 12 November 2026, on time. Timely debt servicing confirmed for investors under Regulation 57.
- Value
- ₹0.07 Cr
Kirloskar Electric Company Debt & Borrowing: ₹100 Cr
Kirloskar Electric executed a Rs 100 Crore Master Facility Agreement with Kotak Mahindra Bank for working capital credit facilities. The facility is secured by current assets, a property, guarantees and fixed deposit lien.
- Value
- ₹100.0 Cr
Niva Bupa Health Insurance Company Debt & Borrowing: ₹150 Cr
Niva Bupa redeemed Rs. 150 Crore debentures via call option on 13 November 2026. Payment came early because the 15 November due date was a non-business day.
- Value
- ₹150.0 Cr